Areteia Therapeutics Announces Additional $75MM in Series A Financing for Oral Dexpramipexole in Eosinophilic Asthma

Contributed by: Business Wire

Logo

Tags

Biotechnology

Pharmaceutical

Health

Areteia Therapeutics, Inc.

More Like This

Areteia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024

(Photo: Business Wire)

Areteia Therapeutics Announces Appointment of Daniel Becker, M.D., Ph.D. To Board of Directors

Athos Announces Positive Topline Phase 1 Data for its AI-Generated, Novel, Oral G9A Inhibitor ATH-063, Demonstrating Selective Expansion and Activation of Potent Anti-Inflammatory Regulatory T Cells

UNION therapeutics announces successful completion of the ADESOS Phase 2b study and presentation of data at the RAVE Conference 2024

iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates

Orexo's OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC

iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress

Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout